Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata

PLoS Pathogens

Volumn 8, Issue 5, 2012, Pages

  Singh Babak, Sheena D ^a   Babak, Tomas ^b   Diezmann, Stephanie ^a   Hill, Jessica A ^a   Xie, Jinglin Lucy ^a   Chen, Ying Lien ^c   Poutanen, Susan M ^a,d   Rennie, Robert P ^e   Heitman, Joseph ^c   Cowen, Leah E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b STANFORD UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; ECHINOCANDIN; HEAT SHOCK PROTEIN 90; ANTIFUNGAL AGENT; CALCINEURIN; FUNGAL PROTEIN; GLUCOSYLTRANSFERASE;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; FUNGAL GENOME; GENE MUTATION; GENE SEQUENCE; IN VITRO STUDY; NONHUMAN; CANDIDEMIA; DNA SEQUENCE; DRUG EFFECT; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MOLECULAR EVOLUTION; NUCLEOTIDE SEQUENCE;

CANDIDA; CANDIDA GLABRATA; MURINAE; MUS;

ANTIFUNGAL AGENTS; BASE SEQUENCE; CALCINEURIN; CANDIDA GLABRATA; CANDIDEMIA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; EVOLUTION, MOLECULAR; FEMALE; FUNGAL PROTEINS; GENOME, FUNGAL; GLUCOSYLTRANSFERASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 84863666582     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002718     Document Type: Article

References (130)

1. Anderson JB, (2005) Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 3: 547-556.
2. Antonovics J, Abbate JL, Baker CH, Daley D, Hood ME, et al. (2007) Evolution by any other name: antibiotic resistance and avoidance of the E-word. PLoS Biol 5: e30.
3. Cowen LE, (2008) The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat Rev Microbiol 6: 187-198.
4. Levin BR, Lipsitch M, Bonhoeffer S, (1999) Population biology, evolution, and infectious disease: convergence and synthesis. Science 283: 806-809.
5. Palumbi SR, (2001) Humans as the world's greatest evolutionary force. Science 293: 1786-1790.
6. Martin GS, Mannino DM, Eaton S, Moss M, (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554.
7. Pfaller MA, Diekema DJ, (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
8. Finkel JS, Mitchell AP, (2011) Genetic control of Candida albicans biofilm development. Nat Rev Microbiol 9: 109-118.
9. Kircher M, Kelso J, (2010) High-throughput DNA sequencing-concepts and limitations. Bioessays 32: 524-536.
10. Mardis ER, (2008) Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 9: 387-402.
11. Nowrousian M, (2010) Next-generation sequencing techniques for eukaryotic microorganisms: sequencing-based solutions to biological problems. Eukaryot Cell 9: 1300-1310.
12. Harris SR, Feil EJ, Holden MT, Quail MA, Nickerson EK, et al. (2010) Evolution of MRSA during hospital transmission and intercontinental spread. Science 327: 469-474.
13. Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, et al. (2011) Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 43: 482-486.
14. Lee HH, Molla MN, Cantor CR, Collins JJ, (2010) Bacterial charity work leads to population-wide resistance. Nature 467: 82-85.
15. Cowen LE, Nantel A, Whiteway MS, Thomas DY, Tessier DC, et al. (2002) Population genomics of drug resistance in Candida albicans. Proc Natl Acad Sci U S A 99: 9284-9289.
16. Selmecki AM, Dulmage K, Cowen LE, Anderson JB, Berman J, (2009) Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet 5: e1000705.
17. Cowen LE, Anderson JB, Kohn LM, (2002) Evolution of drug resistance in Candida albicans. Annu Rev Microbiol 56: 139-165.
18. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, et al. (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41: 1232-1239.
19. Fidel PL Jr, Vazquez JA, Sobel JD, (1999) Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 12: 80-96.
20. Shapiro RS, Robbins N, Cowen LE, (2011) Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev 75: 213-267.
21. Dujon B, Sherman D, Fischer G, Durrens P, Casaregola S, et al. (2004) Genome evolution in yeasts. Nature 430: 35-44.
22. Marcet-Houben M, Gabaldon T, (2009) The tree versus the forest: the fungal tree of life and the topological diversity within the yeast phylome. PLoS One 4: e4357.
23. Fitzpatrick DA, Logue ME, Stajich JE, Butler G, (2006) A fungal phylogeny based on 42 complete genomes derived from supertree and combined gene analysis. BMC Evol Biol 6: 99.
24. Butler G, Rasmussen MD, Lin MF, Santos MA, Sakthikumar S, et al. (2009) Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature 459: 657-662.
25. Lin CY, Chen YC, Lo HJ, Chen KW, Li SY, (2007) Assessment of Candida glabrata strain relatedness by pulsed-field gel electrophoresis and multilocus sequence typing. J Clin Microbiol 45: 2452-2459.
26. Brockert PJ, Lachke SA, Srikantha T, Pujol C, Galask R, et al. (2003) Phenotypic switching and mating type switching of Candida glabrata at sites of colonization. Infect Immun 71: 7109-7118.
27. Butler G, (2010) Fungal sex and pathogenesis. Clin Microbiol Rev 23: 140-159.
28. Muller H, Thierry A, Coppee JY, Gouyette C, Hennequin C, et al. (2009) Genomic polymorphism in the population of Candida glabrata: gene copy-number variation and chromosomal translocations. Fungal Genet Biol 46: 264-276.
29. Polakova S, Blume C, Zarate JA, Mentel M, Jorck-Ramberg D, et al. (2009) Formation of new chromosomes as a virulence mechanism in yeast Candida glabrata. Proc Natl Acad Sci U S A 106: 2688-2693.
30. Selmecki A, Forche A, Berman J, (2006) Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313: 367-370.
31. Selmecki A, Gerami-Nejad M, Paulson C, Forche A, Berman J, (2008) An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol 68: 624-641.
32. Cowen LE, Steinbach WJ, (2008) Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 7: 747-764.
33. Perlin DS, (2007) Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 10: 121-130.
34. Katiyar S, Pfaller M, Edlind T, (2006) Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 50: 2892-2894.
35. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS, (2008) Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 52: 2263-2265.
36. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS, (2009) Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 53: 3690-3699.
37. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, et al. (2010) Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 48: 2373-2380.
38. Balashov SV, Park S, Perlin DS, (2006) Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 50: 2058-2063.
39. Garcia-Effron G, Park S, Perlin DS, (2009) Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 53: 112-122.
40. Castanheira M, Woosley LN, Diekema DJ, Messer SA, Jones RN, et al. (2010) Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother 54: 2655-2659.
41. Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, et al. (2009) Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 5: e1000532.
42. Taipale M, Jarosz DF, Lindquist S, (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11: 515-528.
43. Wandinger SK, Richter K, Buchner J, (2008) The Hsp90 chaperone machinery. J Biol Chem 283: 18473-18477.
44. Cowen LE, Lindquist S, (2005) Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309: 2185-2189.
45. Cowen LE, Singh SD, Kohler JR, Collins C, Zaas AK, et al. (2009) Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A 106: 2818-2823.
46. LaFayette SL, Collins C, Zaas AK, Schell WA, Betancourt-Quiroz M, et al. (2010) PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog 6: e1001069.
47. Cowen LE, Carpenter AE, Matangkasombut O, Fink GR, Lindquist S, (2006) Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell 5: 2184-2188.
48. Miyazaki T, Inamine T, Yamauchi S, Nagayoshi Y, Saijo T, et al. (2010) Role of the Slt2 mitogen-activated protein kinase pathway in cell wall integrity and virulence in Candida glabrata. FEMS Yeast Res 10: 343-352.
49. Miyazaki T, Yamauchi S, Inamine T, Nagayoshi Y, Saijo T, et al. (2010) Roles of calcineurin and Crz1 in antifungal susceptibility and virulence of Candida glabrata. Antimicrob Agents Chemother 54: 1639-1643.
50. Hernandez S, Lopez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, et al. (2004) Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 48: 1382-1383.
51. Coste A, Selmecki A, Forche A, Diogo D, Bougnoux ME, et al. (2007) Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell 6: 1889-1904.
52. Dunkel N, Blass J, Rogers PD, Morschhauser J, (2008) Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol Microbiol 69: 827-840.
53. Hoot SJ, Smith AR, Brown RP, White TC, (2011) An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrob Agents Chemother 55: 940-942.
54. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, et al. (2001) Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45: 2676-2684.
55. White TC, (1997) Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41: 1482-1487.
56. Clinical and Laboratory Standards Institute (2008) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard, Third Edition, Document M27-A3 Wayne, PA Clinical and Laboratory Standards Institute.
57. Sherman DJ, Martin T, Nikolski M, Cayla C, Souciet JL, et al. (2009) Genolevures: protein families and synteny among complete hemiascomycetous yeast proteomes and genomes. Nucleic Acids Res 37: D550-554.
58. Ashrafi K, Farazi TA, Gordon JI, (1998) A role for Saccharomyces cerevisiae fatty acid activation protein 4 in regulating protein N-myristoylation during entry into stationary phase. J Biol Chem 273: 25864-25874.
59. Martinez MJ, Roy S, Archuletta AB, Wentzell PD, Anna-Arriola SS, et al. (2004) Genomic analysis of stationary-phase and exit in Saccharomyces cerevisiae: gene expression and identification of novel essential genes. Mol Biol Cell 15: 5295-5305.
60. McClellan AJ, Xia Y, Deutschbauer AM, Davis RW, Gerstein M, et al. (2007) Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 131: 121-135.
61. Bennett RJ, Johnson AD, (2006) The role of nutrient regulation and the Gpa2 protein in the mating pheromone response of C. albicans. Mol Microbiol 62: 100-119.
62. Ramsdale M, Selway L, Stead D, Walker J, Yin Z, et al. (2008) MNL1 regulates weak acid-induced stress responses of the fungal pathogen Candida albicans. Mol Biol Cell 19: 4393-4403.
63. Bonhomme J, Chauvel M, Goyard S, Roux P, Rossignol T, et al. (2011) Contribution of the glycolytic flux and hypoxia adaptation to efficient biofilm formation by Candida albicans. Mol Microbiol 80: 995-1013.
64. Hwang PK, Tugendreich S, Fletterick RJ, (1989) Molecular analysis of GPH1, the gene encoding glycogen phosphorylase in Saccharomyces cerevisiae. Mol Cell Biol 9: 1659-1666.
65. Sunnarborg SW, Miller SP, Unnikrishnan I, LaPorte DC, (2001) Expression of the yeast glycogen phosphorylase gene is regulated by stress-response elements and by the HOG MAP kinase pathway. Yeast 18: 1505-1514.
66. Copping VM, Barelle CJ, Hube B, Gow NA, Brown AJ, et al. (2005) Exposure of Candida albicans to antifungal agents affects expression of SAP2 and SAP9 secreted proteinase genes. J Antimicrob Chemother 55: 645-654.
67. Cocker JH, Piatti S, Santocanale C, Nasmyth K, Diffley JF, (1996) An essential role for the Cdc6 protein in forming the pre-replicative complexes of budding yeast. Nature 379: 180-182.
68. Detweiler CS, Li JJ, (1997) Cdc6p establishes and maintains a state of replication competence during G1 phase. J Cell Sci 110 (Pt 6): 753-763.
69. Creutz CE, Snyder SL, Schulz TA, (2004) Characterization of the yeast tricalbins: membrane-bound multi-C2-domain proteins that form complexes involved in membrane trafficking. Cell Mol Life Sci 61: 1208-1220.
70. Huh WK, Falvo JV, Gerke LC, Carroll AS, Howson RW, et al. (2003) Global analysis of protein localization in budding yeast. Nature 425: 686-691.
71. Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, et al. (2010) FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 54: 5042-5047.
72. Singer MS, Kahana A, Wolf AJ, Meisinger LL, Peterson SE, et al. (1998) Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics 150: 613-632.
73. Zhu C, Byers KJ, McCord RP, Shi Z, Berger MF, et al. (2009) High-resolution DNA-binding specificity analysis of yeast transcription factors. Genome Res 19: 556-566.
74. Lorenz MC, Heitman J, (1998) Regulators of pseudohyphal differentiation in Saccharomyces cerevisiae identified through multicopy suppressor analysis in ammonium permease mutant strains. Genetics 150: 1443-1457.
75. Kitakawa M, Graack HR, Grohmann L, Goldschmidt-Reisin S, Herfurth E, et al. (1997) Identification and characterization of the genes for mitochondrial ribosomal proteins of Saccharomyces cerevisiae. Eur J Biochem 245: 449-456.
76. Bui DM, Jarosch E, Schweyen RJ, (1997) The yeast ORF YDL202w codes for the mitochondrial ribosomal protein YmL11. Curr Genet 31: 396-400.
77. Laurino JP, Thompson GM, Pacheco E, Castilho BA, (1999) The beta subunit of eukaryotic translation initiation factor 2 binds mRNA through the lysine repeats and a region comprising the C2-C2 motif. Mol Cell Biol 19: 173-181.
78. Healy AM, Zolnierowicz S, Stapleton AE, Goebl M, DePaoli-Roach AA, et al. (1991) CDC55, a Saccharomyces cerevisiae gene involved in cellular morphogenesis: identification, characterization, and homology to the B subunit of mammalian type 2A protein phosphatase. Mol Cell Biol 11: 5767-5780.
79. Wang Y, Burke DJ, (1997) Cdc55p, the B-type regulatory subunit of protein phosphatase 2A, has multiple functions in mitosis and is required for the kinetochore/spindle checkpoint in Saccharomyces cerevisiae. Mol Cell Biol 17: 620-626.
80. Queralt E, Lehane C, Novak B, Uhlmann F, (2006) Downregulation of PP2A (Cdc55) phosphatase by separase initiates mitotic exit in budding yeast. Cell 125: 719-732.
81. Bizzari F, Marston AL, (2011) Cdc55 coordinates spindle assembly and chromosome disjunction during meiosis. J Cell Biol 193: 1213-1228.
82. Douglas CM, (2001) Fungal beta(1,3)-D-glucan synthesis. Med Mycol 39 (Suppl 1): 55-66.
83. Douglas CM, Foor F, Marrinan JA, Morin N, Nielsen JB, et al. (1994) The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc Natl Acad Sci U S A 91: 12907-12911.
84. Andersson DI, Hughes D, (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8: 260-271.
85. Levin BR, Perrot V, Walker N, (2000) Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154: 985-997.
86. Schulz zur Wiesch P, Engelstadter J, Bonhoeffer S, (2010) Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicrob Agents Chemotherapy 54: 2085-2095.
87. Tanaka MM, Valckenborgh F, (2011) Escaping an evolutionary lobster trap: drug resistance and compensatory mutation in a fluctuating environment. Evolution 65: 1376-1387.
88. Ben-Ami R, Kontoyiannis DP, (2012) Resistance to echinocandins comes at a cost: The impact of FKS1 hotspot mutations on Candida albicans fitness and virulence. Virulence 3: 95-7.
89. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, et al. (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42: 260-266.
90. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM, (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91: 8324-8328.
91. Imai J, Yahara I, (2000) Role of HSP90 in salt stress tolerance via stabilization and regulation of calcineurin. Mol Cell Biol 20: 9262-9270.
92. Steinbach WJ, Reedy JL, Cramer RA Jr, Perfect JR, Heitman J, (2007) Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 5: 418-430.
93. Hemenway CS, Heitman J, (1999) Calcineurin. Structure, function, and inhibition. Cell Biochem Biophys 30: 115-151.
94. Inoue SB, Takewaki N, Takasuka T, Mio T, Adachi M, et al. (1995) Characterization and gene cloning of 1,3-beta-D-glucan synthase from Saccharomyces cerevisiae. Eur J Biochem 231: 845-854.
95. Lesage G, Sdicu AM, Menard P, Shapiro J, Hussein S, et al. (2004) Analysis of beta-1,3-glucan assembly in Saccharomyces cerevisiae using a synthetic interaction network and altered sensitivity to caspofungin. Genetics 167: 35-49.
96. Mazur P, Morin N, Baginsky W, el-Sherbeini M, Clemas JA, et al. (1995) Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol 15: 5671-5681.
97. Zhao C, Jung US, Garrett-Engele P, Roe T, Cyert MS, et al. (1998) Temperature-induced expression of yeast FKS2 is under the dual control of protein kinase C and calcineurin. Mol Cell Biol 18: 1013-1022.
98. Brun S, Berges T, Poupard P, Vauzelle-Moreau C, Renier G, et al. (2004) Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob Agents Chemother 48: 1788-1796.
99. Cheng S, Clancy CJ, Nguyen KT, Clapp W, Nguyen MH, (2007) A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole. Antimicrob Agents Chemother 51: 1855-1858.
100. Kontoyiannis DP, (2000) Modulation of fluconazole sensitivity by the interaction of mitochondria and erg3p in Saccharomyces cerevisiae. J Antimicrob Chemother 46: 191-197.
101. Sanglard D, Ischer F, Bille J, (2001) Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob Agents Chemother 45: 1174-1183.
102. Ferrari S, Sanguinetti M, De Bernardis F, Torelli R, Posteraro B, et al. (2011) Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice. Antimicrob Agents Chemotherapy 55: 1852-1860.
103. Bouchara JP, Zouhair R, Le Boudouil S, Renier G, Filmon R, et al. (2000) In-vivo selection of an azole-resistant petite mutant of Candida glabrata. J Med Microbiol 49: 977-984.
104. Brun S, Dalle F, Saulnier P, Renier G, Bonnin A, et al. (2005) Biological consequences of petite mutations in Candida glabrata. J Antimicrob Chemother 56: 307-314.
105. Chen YL, Kauffman S, Reynolds TB, (2008) Candida albicans uses multiple mechanisms to acquire the essential metabolite inositol during infection. Infect Immun 76: 2793-2801.
106. Shapiro RS, Uppuluri P, Zaas AK, Collins C, Senn H, et al. (2009) Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling. Curr Biol 19: 621-629.
107. Cowen LE, Sanglard D, Calabrese D, Sirjusingh C, Anderson JB, et al. (2000) Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 182: 1515-1522.
108. Cowen LE, Kohn LM, Anderson JB, (2001) Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 183: 2971-2978.
109. Bachmann SP, Patterson TF, Lopez-Ribot JL, (2002) In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 40: 2228-2230.
110. Niimi K, Maki K, Ikeda F, Holmes AR, Lamping E, et al. (2006) Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob Agents Chemother 50: 1148-1155.
111. Posteraro B, Sanguinetti M, Fiori B, La Sorda M, Spanu T, et al. (2006) Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes. J Antimicrob Chemother 58: 458-461.
112. Schuetzer-Muehlbauer M, Willinger B, Egner R, Ecker G, Kuchler K, (2003) Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast. Int J Antimicrob Agents 22: 291-300.
113. Dagley MJ, Gentle IE, Beilharz TH, Pettolino FA, Djordjevic JT, et al. (2011) Cell wall integrity is linked to mitochondria and phospholipid homeostasis in Candida albicans through the activity of the post-transcriptional regulator Ccr4-Pop2. Mol Microbiol 79: 968-989.
114. Rodaki A, Young T, Brown AJ, (2006) Effects of depleting the essential central metabolic enzyme fructose-1,6-bisphosphate aldolase on the growth and viability of Candida albicans: implications for antifungal drug target discovery. Eukaryot Cell 5: 1371-1377.
115. Borah S, Shivarathri R, Kaur R, (2011) The Rho1 GTPase-activating protein CgBem2 is required for survival of azole stress in Candida glabrata. J Biol Chem 286: 34311-34324.
116. Blankenship JR, Fanning S, Hamaker JJ, Mitchell AP, (2010) An extensive circuitry for cell wall regulation in Candida albicans. PLoS Pathog 6: e1000752.
117. Netea MG, Brown GD, Kullberg BJ, Gow NA, (2008) An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 6: 67-78.
118. Pfaller MA, Diekema DJ, (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36: 1-53.
119. Robbins N, Uppuluri P, Nett J, Rajendran R, Ramage G, et al. (2011) Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog 7: e1002257.
120. Marchetti O, Moreillon P, Entenza JM, Vouillamoz J, Glauser MP, et al. (2003) Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes. Antimicrob Agents Chemother 47: 1565-1570.
121. Onyewu C, Afshari NA, Heitman J, (2006) Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. Antimicrob Agents Chemother 50: 3963-3965.
122. Uppuluri P, Nett J, Heitman J, Andes D, (2008) Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 52: 1127-1132.
123. Kumar R, Musiyenko A, Barik S, (2005) Plasmodium falciparum calcineurin and its association with heat shock protein 90: mechanisms for the antimalarial activity of cyclosporin A and synergism with geldanamycin. Mol Biochem Parasitol 141: 29-37.
124. Naderer T, Dandash O, McConville MJ, (2011) Calcineurin is required for Leishmania major stress response pathways and for virulence in the mammalian host. Mol Microbiol 80: 471-480.
125. Pallavi R, Roy N, Nageshan RK, Talukdar P, Pavithra SR, et al. (2010) Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J Biol Chem 285: 37964-37975.
126. Shahinas D, Liang M, Datti A, Pillai DR, (2010) A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med Chem 53: 3552-3557.
127. Prodromou C, (2009) Strategies for stalling malignancy: targeting cancer's addiction to Hsp90. Curr Top Med Chem 9: 1352-1368.
128. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, et al. (2009) Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 9: 1479-1492.
129. Chen KW, Lo HJ, Lin YH, Li SY, (2005) Comparison of four molecular typing methods to assess genetic relatedness of Candida albicans clinical isolates in Taiwan. J Med Microbiol 54: 249-258.
130. Babak T, Deveale B, Armour C, Raymond C, Cleary MA, et al. (2008) Global survey of genomic imprinting by transcriptome sequencing. Curr Biol 18: 1735-1741.